About this role
Supervisors:
Prof. Jeremy Brown
Prof. Bart Hoogenboom
Abstract
This project explores a novel therapeutic strategy for Acinetobacter baumannii, a top-priority AMR pathogen, by investigating the synergistic effects of monoclonal antibodies and colistin. Building on extensive preliminary data, the project aims to uncover the mechanisms behind this synergy using advanced biophysical and molecular techniques. The findings will lay the groundwork for clinical application and contribute to the development of targeted therapies for resistant bacterial infections.
Approach and Methods
Atomic force microscopy (AFM) for molecular-scale visualisation of living bacteria. In vitro assays to measure growth and stress responses. RNA-seq to analyse gene expression under treatment conditions.
Impact and Outlook
This project will
Establish mechanistic foundations for a new therapeutic strategy. Support clinical translation of antibody–antibiotic combinations. Contribute to global AMR mitigation efforts.
Training and Student Development
The successful applicant will gain expertise in:
Biophysical imaging (AFM, microscopy) Microbiology and molecular biology RNA sequencing and data analysis Interdisciplinary collaboration across clinical and physical sciences
Research Environment
Hoogenboom Lab: Pioneers in AFM imaging of bacteria, supported by BBSRC and Wellcome.
Brown Lab: Leader in pneumonia pathogenesis, equipped for microbiology and screening assays, MRC and Wellcome-funded.
Both labs promote an open, collaborative culture and have a strong track record of PhD supervision.
Desirable Prior Experience
Some prior experience in basic microbiology, immunology, and/or microscopy would be an advantage, but not essential.
How to apply
This project is offered as part of the Centre for Doctoral Training in Engineering Solutions for Antimicrobial Resistance. Further details about the CDT and programme can be found at AMR CDT webiste
Applications should be submitted by 12th January 2026.